KardiaMobile

KardiaMobile is the most widely-used, clinically-validated ECG in the world — producing a single-lead ECG comparable to Lead 1 of a traditional 12-lead ECG in just 30 seconds. KardiaMobile is FDA-cleared to detect atrial fibrillation and normal sinus rhythm, offering you and your patients valuable information when they’re feeling a symptom.

 

KardiaMobile

A clinically-validated alternative for ambulatory ECG

  1. 98% sensitive and 97% specific in the detection of Atrial Fibrillation 1

  2. Provides a diagnostic yield comparable to a 14-day ambulatory event monitor 2

  3. The most clinically-validated portable ECG solution available

  4. KardiaMobile has delivered more than 30 million ECGs worldwide

1. Lau JK, Lowres N, Neubeck L, Brieger DB, Sy RW, Galloway CD, et al. Int J Cardiol. 2013;165(1):193-4.

2. Narasimha D, Hanna N, Beck H, Chaskes M, Glover R, Gatewood R, et al. Validation of a smartphone-based event recorder for arrhythmia detection. Pacing Clin Electrophysiol. 2018.

Clinical Validation Studies

  1. Post-Surgery

    Self-monitoring with KardiaMobile improves AFib detection and self-reported quality of life.

    Lowres N et al., Eur J Cardiothorac Surg, 2016

    Read the report

  2. Post-Ablation

    KardiaMobile smartphone-based ECG monitors added to the 2017 consensus guidelines for patients post-ablation.

    HRS Consensus Statement, 2017

    Read the report

  3. Quality of Life

    Self-monitoring with KardiaMobile improves AFib detection and self-reported quality of life.

    iHEART study, J Atr Fibrillation , 2017

    Read the report

“It makes patients a partner in their healthcare.”
Dr. Anne Curtis, Cardiologist
Chairman, Internal Medicine
University at Buffalo

Top Cardiologists Choose KardiaMobile

Patients are engaged in their own healthcare like never before. Affordable and discrete, patients can take action when they feel a symptom to conveniently self-monitor their heart short or long-term.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Read our cookie policy ×